[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cone-rod-dystrophy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cone-rod-dystrophy":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,96,125,158,196,232],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":54,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":95},"100242565","inherited-retinal-degenerative-disease-registry-100242565",false,"NCT02435940","Inherited Retinal Degenerative Disease Registry","Foundation Fighting Blindness My Retina Tracker Registry","MRTR","Inclusion Criteria:\n\n* Diagnosed with an inherited retinal degenerative disease OR\n\nExclusion Criteria:\n\n* Glaucoma only\n* Diabetic retinopathy only\n* Non-retinal disease\n* Not heritable retinal disease",true,"ALL",{"count":20,"type":21},20000,"ESTIMATED","20 Years","OBSERVATIONAL","The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by the Foundation. It is a patient-initiated registry accessible via a secure on-line portal at www.MyRetinaTracker.org. Affected individuals who register are guided to create a profile that captures their perspective on their retinal disease and its progress; family history; genetic testing results; preventive measures; general health and interest in participation in research studies. The participants may also choose to ask their clinician to add clinical measurements and results at each clinical visit. Participants are urged to update the information regularly to create longitudinal records of their disease, from their own perspective, and their clinical progress. The overall goals of the Registry are: to better understand the diversity within the inherited retinal degenerative diseases; to understand the prevalence of the different diseases and gene variants; to assist in the establishment of genotype-phenotype relationships; to help understand the natural history of the diseases; to help accelerate research and development of clinical trials for treatments; and to provide a tool to investigators that can assist with recruitment for research studies and clinical trials.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53],"Eye Diseases Hereditary","Retinal Disease","Achromatopsia","Bardet-Biedl Syndrome","Bassen-Kornzweig Syndrome","Batten Disease","Best Disease","Choroidal Dystrophy","Choroideremia","Cone Dystrophy","Cone-Rod Dystrophy","Congenital Stationary Night Blindness","Enhanced S-Cone Syndrome","Fundus Albipunctatus","Goldmann-Favre Syndrome","Gyrate Atrophy","Juvenile Macular Degeneration","Kearns-Sayre Syndrome","Leber Congenital Amaurosis","Refsum Syndrome","Retinitis Pigmentosa","Retinitis Punctata Albescens","Retinoschisis","Rod-Cone Dystrophy","Rod Dystrophy","Rod Monochromacy","Stargardt Disease","Usher Syndrome",[55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82],"inherited retinal degenerative disease","retinitis pigmentosa","Usher","Leber","Bardet-Biedl","Batten","Best","cone dystrophy","cone-rod dystrophy","choroideremia","congenital night blindness","enhanced s-cone","cone monochromacy","Goldmann-Favre","Kearns-Sayre","Refsum","retinoschisis","rod-cone dystrophy","rod dystrophy","rod monochromacy","Sorsby pseudoinflammatory dystrophy","stargardt","achromatopsia","juvenile inherited macular degeneration","cone dichromacy","cone trichromacy","Charcot-Marie-Tooth","albipunctate dystrophy","RECRUITING","2026-05-18",{"date":86,"type":87},"2026-05-19","ACTUAL",{"date":89,"type":4},"2014-06",{"date":91,"type":21},"2037-06",{"name":93,"class":94},"Foundation Fighting Blindness","OTHER",1,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":18,"minAge":102,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":124},"100466567","adaptive-optics-imaging-of-outer-retinal-diseases-100466567","NCT05355415","Adaptive Optics Imaging of Outer Retinal Diseases","Inclusion Criteria:\n\n1. Are 21 years of age or older,\n2. Have the ability to cooperate with instructions during adaptive optics imaging (similar to instructions given during a clinical eye exam),\n3. Have the ability to understand and sign an informed consent. (Non-English speaking participants will not be enrolled into the study), and\n4. Have been diagnosed with outer retinal disease or condition (Cohort 2).\n\nExclusion Criteria:\n\n1. Have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity),\n2. Have visual correction outside of the range +4 diopters (D) to -8 D,\n3. Have a history of adverse reaction to mydriatic drops,\n4. Have a predisposition to (i.e., narrow iridocorneal angle) or any history of acute angle closure glaucoma (AACG), or\n5. Are working under the direct supervision of Drs. Hammer, Cukras and Liu, or any of the NIH\u002FNEI AIs.","21 Years",{"count":104,"type":21},100,"The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints.",[107,108,46,109,110,111,35,112,113,50],"Retinal Degeneration","Age-Related Macular Degeneration","Hydroxychloroquine Retinopathy","Usher Syndromes","Late-Onset Retinal Degeneration","Cone Rod Dystrophy","Rod Cone Dystrophy","2026-05-06",{"date":116,"type":87},"2026-05-08",{"date":118,"type":87},"2021-08-27",{"date":120,"type":21},"2028-09-30",{"name":122,"class":123},"Food and Drug Administration (FDA)","FED",2,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":18,"minAge":133,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":95},"100635150","observational-study-to-investigate-the-short-term-effects-of-transcorneal-electrical-stimulation-on-visual-performance-100635150","NCT07548944","Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual Performance","Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation (TES) on Visual Performance in Patients With Retinitis Pigmentosa and Similar Retinal Diseases","TES-STEP","Inclusion Criteria:\n\n* Adult patients (≥ 18 years) with clinically diagnosed retinitis pigmentosa (RP) or other similar degenerative retinal disease\n* Current treatment with TES using the OkuStim® System within the intended purpose\n* Subjective perception of short-term effects after TES treatment\n* Ability and willingness to give informed consent\n\nExclusion Criteria:\n\n* Cognitive, psychological, or linguistic limitations that prevent informed consent or proper study participation\n* Presence of other eye diseases (e.g., cataract, glaucoma, macular degeneration) that, in the opinion of the investigator, compromise or confound study assessments\n* Simultaneous participation in other clinical studies that could influence the results of the study\n* Severe comorbidities that could compromise patient safety or study conduct","18 Years",{"count":135,"type":21},30,"Retinitis pigmentosa and similar degenerative diseases of the retina lead to progressive loss of vision. TES therapy with the CE-marked OkuStim® System is a treatment approved in the EU for slowing the progression of the disease. Patients increasingly report short-term subjective improvements in vision, which have not yet been systematically investigated. This exploratory study is conducted to determine whether these subjective short-term effects can be measured, and therefore also be quantified, by objective tests.",[138,53,112],"Retinitis Pigmentosa (RP)",[140,141,142,143,144,145,146,107,147],"Transcorneal Electrical Stimulation","TES","OkuStim","Okuvision","Retinitis pigmentosa","Eye Diseases","Retinal Dystrophies","Retinal Diseases","2026-04-30",{"date":150,"type":87},"2026-05-01",{"date":152,"type":87},"2026-04-20",{"date":154,"type":21},"2027-03",{"name":156,"class":157},"Okuvision GmbH","INDUSTRY",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":18,"minAge":133,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":168,"phases":169,"briefSummary":172,"conditions":173,"keywords":178,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":195},"100576757","phase-1-a-study-to-investigate-the-safety-of-opct-001-in-adults-who-have-primary-photoreceptor-disease-clarico-100576757","NCT06789445","A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)","A Phase 1\u002F2a Study of Subretinal Administration of OpCT-001 Photoreceptor Precursor Cells Derived From iPSCs in Patients With Primary Photoreceptor Disease","CLARICO","Key Inclusion Criteria:\n\n* Confirmed genetic diagnosis of primary photoreceptor (PR) disease\n* Best corrected visual acuity (BCVA) in the study eye at Screening for Phase 1: Logmarithm of the minimum angle of resolution (LogMAR) 3.9 to LogMAR 1.3. BCVA at Screening for Phase 2: ETDRS letter score between 20 to 60, inclusive.\n* Retinal structure examination in the study eye demonstrating regions suitable for cell administration.\n\nKey Exclusion Criteria:\n\n* Clinically relevant, active ocular inflammation or infection\n* Glaucoma or other significant optic neuropathy\n* Diabetic macular edema or diabetic retinopathy\n* Clinically significant cystoid macular edema\n* In phakic participants: Spherical equivalent refractive error of greater than 8.00 diopters myopia\n* Ocular surgery ≤3 months before Screening\n* Monocular vision (ie, no light perception in the fellow eye)\n* Currently active malignancy, or history of malignancy within 5 years before OpCT-001 administration. Exception: Basal cell carcinoma that has been definitively treated.\n* Any current and active infection (bacterial\u002Fviral\u002Ffungal) that could put the participant at risk from immunosuppression\n* History of any cell therapy, gene therapy, or retinal implant at any time\n* Previously received a bone marrow or solid organ transplant",{"count":167,"type":21},54,"INTERVENTIONAL",[170,171],"PHASE1","PHASE2","Study OpCT-001-101 is a Phase 1\u002F2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in approximately 54 adults with primary photoreceptor (PR) disease. Phase 1 focuses on safety and features a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT-001 on measures of visual function, functional vision, and anatomic measures of engraftment in different clinical subgroups.",[174,138,53,175,49,176,107,177,36],"Primary Photoreceptor Disease","Inherited Retinal Disease (IRD)","Rod-Cone Disease","Cone-Rod Disease (C-RD)",[164,179,180,181,53,46,182,183,184,185],"Photoreceptor cells","Cell Therapy","Cellular Therapy","Inherited retinal disease (IRD)","Primary Photoreceptor disease (PPD)","Rod-Con Disease (R-CD)","Cone-Rose disease (C-RD)","2026-04-07",{"date":188,"type":87},"2026-04-13",{"date":190,"type":87},"2025-03-10",{"date":192,"type":21},"2030-10",{"name":194,"class":157},"BlueRock Therapeutics",4,{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":18,"minAge":203,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":231},"100550303","prescreening-study-to-identify-potential-stargardt-participants-for-acdn-01-clinical-trials-starpath-100550303","NCT06445322","Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)","Prescreening Study to Identify Potential Participants With ABCA4-related Retinopathy for ACDN-01 Clinical Trials","Key Inclusion Criteria:\n\n* Presence of mutations in the ABCA4 gene\n* ABCA4 retinopathy phenotype (Stargardt disease type 1 or cone-rod dystrophy)\n\nKey Exclusion Criteria:\n\n* The presence of pathogenic or likely pathogenic mutations in other genes known to cause cone-rod dystrophy or Stargardt maculopathy\n* Retinal disease other than ABCA4-related retinopathy\n* Presence of a medical condition (systemic or ophthalmic), psychiatric condition, including substance abuse disorder, or physical examination or laboratory finding that may in the opinion of the principal investigator and sponsor preclude adherence to the scheduled study visits, safe participation in the study, or affect the results of the study.","5 Years",{"count":205,"type":21},50,"This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.",[52,208,112,42],"Stargardt Disease 1",[210,211,52,212,213,214,215,216,217,218,219,220,221],"ABCA4","ABCA4-related retinopathy","Stargardt macular dystrophy","Cone rod dystrophy","Gene editing","RNA","Gene Therapy","Exon editing","IRD","Inherited retinal disease","Inherited retinal dystrophy","Inherited retinal degeneration","2026-03-09",{"date":224,"type":87},"2026-03-11",{"date":226,"type":87},"2024-06-20",{"date":228,"type":21},"2030-08-31",{"name":230,"class":157},"Ascidian Therapeutics, Inc",8,{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":18,"minAge":239,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":168,"phases":242,"briefSummary":243,"conditions":244,"keywords":245,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":254},"100551996","phase-1-study-to-evaluate-acdn-01-in-abca4-related-stargardt-retinopathy-stellar-100551996","NCT06467344","Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)","ACDN-01-001: Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Subretinal ACDN-01 in Participants With ABCA4-related Retinopathy","Key Inclusion Criteria:\n\n* Presence of mutations in the ABCA4 gene\n* ABCA4 retinopathy phenotype (Stargardt disease type 1 or cone-rod dystrophy)\n* Area of atrophy located in the macula of the study eye\n* BCVA of 20\u002F50 (0.4 logMAR) or worse\n\nKey Exclusion Criteria:\n\n* The presence of pathogenic or likely pathogenic mutations in other genes known to cause cone-rod dystrophy or Stargardt maculopathy\n* Retinal disease other than ABCA4-related retinopathy\n* Presence of a medical condition (systemic or ophthalmic), psychiatric condition, including substance abuse disorder, or physical examination or laboratory finding that may in the opinion of the principal investigator and sponsor preclude adherence to the scheduled study visits, safe participation in the study, or affect the results of the study.","12 Years",{"count":241,"type":21},15,[170,171],"This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.",[52,112,42,208],[210,211,52,212,213,214,215,216,217,218,219,220,221],"2025-11-25",{"date":248,"type":87},"2025-12-02",{"date":250,"type":87},"2024-06-11",{"date":252,"type":21},"2030-12-01",{"name":230,"class":157},10]